RU2016134905A - Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря - Google Patents
Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря Download PDFInfo
- Publication number
- RU2016134905A RU2016134905A RU2016134905A RU2016134905A RU2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A RU 2016134905 A RU2016134905 A RU 2016134905A
- Authority
- RU
- Russia
- Prior art keywords
- drug
- composition
- skin
- accelerating
- transdermal
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 10
- 229940079593 drug Drugs 0.000 title claims 9
- 239000000853 adhesive Substances 0.000 title 1
- 230000001070 adhesive effect Effects 0.000 title 1
- 230000035515 penetration Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 2
- 239000012790 adhesive layer Substances 0.000 claims 2
- 229930003935 flavonoid Natural products 0.000 claims 2
- -1 flavonoid compound Chemical class 0.000 claims 2
- 235000017173 flavonoids Nutrition 0.000 claims 2
- 239000010410 layer Substances 0.000 claims 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims 1
- 235000008714 apigenin Nutrition 0.000 claims 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims 1
- 229940117893 apigenin Drugs 0.000 claims 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical group O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims 1
- 150000002215 flavonoids Chemical group 0.000 claims 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims 1
- 235000007743 myricetin Nutrition 0.000 claims 1
- 229940116852 myricetin Drugs 0.000 claims 1
- 235000005875 quercetin Nutrition 0.000 claims 1
- 229960001285 quercetin Drugs 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (16)
1. Композиция для ускорения проникновения через кожу, которая содержит
соединение флавоноида,
при этом композиция используется для ускорения проникновения лекарственного средства через кожу.
2. Композиция для ускорения проникновения через кожу по п. 1,
в которой соединение флавоноида представляет собой соединение, которое имеет флавоновый скелет, представленный формулой (1)
3. Композиция для ускорения проникновения через кожу по п. 2,
в которой соединение, которое имеет флавоновый скелет, представленный формулой (1), представляет собой по меньшей мере одно соединение, выбранное из группы, состоящей из кверцетина, апигенина и мирицетина.
4. Препарат для трансдермального введения, который содержит
лекарственное средство; и
композицию для ускорения проникновения через кожу по п. 1, 2 или 3.
5. Препарат пластыря, который содержит
содержащий лекарственное средство слой, который содержит лекарственное средство и композицию для ускорения проникновения через кожу по п. 1, 2 или 3.
6. Препарат пластыря по п. 5,
в котором содержащий лекарственное средство слой представляет собой содержащий лекарственное средство адгезивный слой, и
содержащий лекарственное средство адгезивный слой предоставлен на одной поверхности основы.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014-014539 | 2014-01-29 | ||
| JP2014014539 | 2014-01-29 | ||
| PCT/JP2015/052388 WO2015115495A1 (ja) | 2014-01-29 | 2015-01-28 | 皮膚透過促進組成物、経皮投与製剤及び貼付製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016134905A true RU2016134905A (ru) | 2018-03-05 |
Family
ID=53757068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016134905A RU2016134905A (ru) | 2014-01-29 | 2015-01-28 | Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170000751A1 (ru) |
| EP (1) | EP3100744A4 (ru) |
| JP (1) | JP2015163606A (ru) |
| KR (1) | KR20160106761A (ru) |
| CN (1) | CN105939729A (ru) |
| BR (1) | BR112016017496A2 (ru) |
| CA (1) | CA2937526A1 (ru) |
| RU (1) | RU2016134905A (ru) |
| WO (1) | WO2015115495A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105380929A (zh) * | 2015-11-23 | 2016-03-09 | 蚌埠丰原涂山制药有限公司 | 一种含洛索洛芬钠的药物组合物及其制备方法 |
| KR102081217B1 (ko) * | 2017-09-13 | 2020-02-25 | 연세대학교 산학협력단 | 네프린 억제제를 유효성분으로 포함하는 피부 투과 촉진용 조성물 |
| CN111135087A (zh) * | 2020-01-09 | 2020-05-12 | 范小玲 | 一种溶剂型透皮贴的工业化制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936611A (ja) * | 1982-08-26 | 1984-02-28 | Nitto Electric Ind Co Ltd | 粘着性貼付製剤 |
| JPS5955822A (ja) * | 1982-09-24 | 1984-03-31 | Nitto Electric Ind Co Ltd | 粘着性貼付製剤用膏体 |
| JPS6137304A (ja) | 1984-07-31 | 1986-02-22 | Nippon Steel Corp | 傾斜ロ−ル圧延機 |
| JPH0429934A (ja) * | 1990-05-28 | 1992-01-31 | Seiichi Umeda | いちょう葉抽出エキスを含有する外用組成物 |
| JPH10139690A (ja) * | 1996-11-02 | 1998-05-26 | Shinichi Konuma | 経皮吸収促進剤 |
| JP4073517B2 (ja) | 1997-04-07 | 2008-04-09 | 久光製薬株式会社 | 経皮吸収貼付剤用粘着剤及び経皮吸収貼付剤 |
| US20030175333A1 (en) * | 2002-03-06 | 2003-09-18 | Adi Shefer | Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin |
| US7241456B2 (en) * | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
| JP4027850B2 (ja) * | 2003-06-20 | 2007-12-26 | ポーラ化成工業株式会社 | 経皮吸収促進化粧料 |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| EP1867323A1 (en) * | 2006-06-13 | 2007-12-19 | Farmatron Ltd. | Pharmaceutical compositions with biological barriers permeation enhancing properties |
| US20100048628A1 (en) * | 2006-12-01 | 2010-02-25 | Sumiyo Nishi | Method for suppressing discoloration over time of adhesive preparation containing donepezil |
| JP5224770B2 (ja) | 2007-03-19 | 2013-07-03 | 金印株式会社 | コラーゲン産生促進剤、促進方法、香粧品、飲食品および医薬品 |
| MX338211B (es) * | 2009-10-22 | 2016-03-30 | Api Genesis Llc | Metodos para hacer y utilizar composiciones que comprenden flavonoides. |
| EP2629763B1 (en) * | 2010-10-22 | 2017-12-06 | Vizuri Health Sciences LLC | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| JP2012206979A (ja) | 2011-03-30 | 2012-10-25 | Ssp Co Ltd | 経皮投与用医薬組成物 |
| JP5856424B2 (ja) | 2011-10-05 | 2016-02-09 | 祐徳薬品工業株式会社 | ロチゴチン含有経皮吸収型貼付剤 |
-
2015
- 2015-01-28 WO PCT/JP2015/052388 patent/WO2015115495A1/ja active Application Filing
- 2015-01-28 JP JP2015014344A patent/JP2015163606A/ja active Pending
- 2015-01-28 CA CA2937526A patent/CA2937526A1/en not_active Abandoned
- 2015-01-28 US US15/113,114 patent/US20170000751A1/en not_active Abandoned
- 2015-01-28 CN CN201580006660.3A patent/CN105939729A/zh active Pending
- 2015-01-28 KR KR1020167022999A patent/KR20160106761A/ko not_active Application Discontinuation
- 2015-01-28 RU RU2016134905A patent/RU2016134905A/ru unknown
- 2015-01-28 BR BR112016017496A patent/BR112016017496A2/pt not_active Application Discontinuation
- 2015-01-28 EP EP15744038.9A patent/EP3100744A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2937526A1 (en) | 2015-08-06 |
| WO2015115495A1 (ja) | 2015-08-06 |
| JP2015163606A (ja) | 2015-09-10 |
| US20170000751A1 (en) | 2017-01-05 |
| EP3100744A1 (en) | 2016-12-07 |
| EP3100744A4 (en) | 2017-08-30 |
| KR20160106761A (ko) | 2016-09-12 |
| CN105939729A (zh) | 2016-09-14 |
| BR112016017496A2 (pt) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| BR112015011112A2 (pt) | composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| BR112017005393A2 (pt) | composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição | |
| UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| CL2013001339A1 (es) | Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih. | |
| CL2013001141A1 (es) | Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c. | |
| TR201908994T4 (tr) | Farmasötik bileşimler. | |
| DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
| CL2014000393A1 (es) | Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion. | |
| CU20140037A7 (es) | Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| CL2014003012A1 (es) | Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c. | |
| ECSP17059323A (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| DK3168214T3 (da) | Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| BR112017004000A2 (pt) | formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida | |
| RU2016134905A (ru) | Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря | |
| CL2014003607A1 (es) | Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer. | |
| BR112017012930A2 (pt) | derivados de imidazopiridazina como inibidores de pi3kbeta. | |
| RU2016134903A (ru) | Композиция для ускорения проникновения через кожу, препарат для трансдермального введения и препарат трансдермального пластыря |